They certainly do a good presentation. They claim to be in discussions and anticipate a partnership to fund their alzheimer's developmental program. If they get that, they are in pretty good shape. They plan on uplisting to Nasdaq this year as well. I think little risk at this price. I don't think they have a "cure" but it is possible they have a better mousetrap than those totally focused on "plaques". JMHO
Market Data 
Markets 
AI
